Ress Life Investments A/S
31.3.2026 17:10:00 CEST | Globenewswire | Press release
Ress Life Investments A/S publishes Net Asset Value (NAV).
Ress Life Investments A/S publishes Net Asset Value (NAV).
Ress Life Investments
Nybrogade 12
DK-1203 Copenhagen K
Denmark
CVR nr. 33593163
www.resslifeinvestments.com
To: Nasdaq Copenhagen
Date: 31 March 2026
Corporate Announcement 13/2026
Ress Life Investments A/S publishes Net Asset Value (NAV).
Ress Life Investments A/S publishes the Net Asset Value (NAV) per share as of 16 March 2026.
NAV per share in USD: 2677.19
The performance during the first half of March is -0.21% in USD. The year-to-date net performance is 1.46% in USD.
Assets under management (AUM) are 213.9 million USD.
The NAV per share in EUR is published on the website of Nasdaq Copenhagen under the section AIF Companies and Funds, where the bid and ask prices are published. The daily NAV in EUR is calculated as the most recently published NAV in USD divided by the European Central Bank’s EUR/USD reference rate on the relevant day.
Questions related to this announcement can be made to the company's AIF-manager, Resscapital AB.
Contact person:
Gustaf Hagerud
gustaf.hagerud@resscapital.com
Tel + 46 73 660 72 42
Note: The terms for subscription of shares, minimum subscription amount and redemption of shares are provided in the Articles of Association, Information Brochure and in the Key Information Document available on the Company's website, www.resslifeinvestments.com.
Attachment
Documents
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Pineal Capital Management31.3.2026 20:13:25 CEST | Press release
Pineal Capital Management Issues Open Letter to the Board of Teladoc Health, Inc.
Ilkka Oyj31.3.2026 18:00:00 CEST | Press release
Ilkka Oyj: Acquisition of own shares on 31 March 2026
Iveco Group N.V.31.3.2026 18:00:00 CEST | Press release
Iveco Group publishes the Informative Document concerning the sale of its Defence business
BioPorto A/S31.3.2026 17:43:41 CEST | Press release
BioPorto Advances U.S. Adult Urine NGAL Program with FDA Pre-Submission Request After Positive EPACRA AKI Cut Off Analysis
BioPorto A/S31.3.2026 17:43:41 CEST | Pressemeddelelse
BioPorto indsender anmodning om FDA pre‑submission for amerikansk voksenprogram for urin‑NGAL efter positiv EPACRA‑analyse af AKI‑cut‑off
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom